Bone imaging in prostate cancer (Q37235929)

19 August 2017

1 reference

title

Bone imaging in prostate cancer (English)

1 reference

19 August 2017

1 reference

Zohar A Dotan

1

1 reference

19 August 2017

language of work or name

English

0 references

publication date

1 August 2008

1 reference

19 August 2017

published in

Nature Reviews Urology

1 reference

19 August 2017

volume

5

1 reference

19 August 2017

issue

8

1 reference

19 August 2017

page(s)

434-444

1 reference

Pathophysiology of bone metastases

19 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1038%2FNCPURO1190

99m Tc-labeled polyphosphate as a skeletal imaging agent

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPURO1190

Accuracy of 99mTC-diphosphonate bone scans and roentgenograms in the detection of prostate, breast and lung carcinoma metastases

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPURO1190

A controlled trial of leuprolide with and without flutamide in prostatic carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPURO1190

21 January 2018

Cancer statistics, 2007

1 reference

https://api.crossref.org/works/10.1038%2FNCPURO1190

7 January 2021

Metastasis to bone: causes, consequences and therapeutic opportunities

1 reference

https://api.crossref.org/works/10.1038%2FNCPURO1190

7 January 2021

Bone scintigraphy, radiographic survey and prostatic acid phosphatase in patients with prostatic carcinoma. A comparison of sensitivity

1 reference

https://api.crossref.org/works/10.1038%2FNCPURO1190

7 January 2021

Mechanisms of bone metastasis

1 reference

https://api.crossref.org/works/10.1038%2FNCPURO1190

7 January 2021

Pathogenesis of bone metastasis: a review

1 reference

https://api.crossref.org/works/10.1038%2FNCPURO1190

7 January 2021

Prostate carcinoma skeletal metastases: cross-talk between tumor and bone.

1 reference

https://api.crossref.org/works/10.1038%2FNCPURO1190

7 January 2021

Management of bone metastases in cancer: a review

1 reference

https://api.crossref.org/works/10.1038%2FNCPURO1190

7 January 2021

Interactions of human prostatic epithelial cells with bone marrow endothelium: binding and invasion

1 reference

https://api.crossref.org/works/10.1038%2FNCPURO1190

7 January 2021

The central role of osteoblasts in the metastasis of prostate cancer

1 reference

https://api.crossref.org/works/10.1038%2FNCPURO1190

7 January 2021

Preferential adhesion of prostate cancer cells to a human bone marrow endothelial cell line

1 reference

https://api.crossref.org/works/10.1038%2FNCPURO1190

7 January 2021

99Tc(m)(V)DMSA scintigraphy in skeletal metastases and superscans arising from various malignancies: diagnosis, treatment monitoring and therapeutic implications

1 reference

https://api.crossref.org/works/10.1038%2FNCPURO1190

7 January 2021

A preoperative nomogram for disease recurrence following radical prostatectomy for prostate cancer

1 reference

https://api.crossref.org/works/10.1038%2FNCPURO1190

7 January 2021

Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer.

1 reference

https://api.crossref.org/works/10.1038%2FNCPURO1190

7 January 2021

Natural history of progression after PSA elevation following radical prostatectomy

1 reference

https://api.crossref.org/works/10.1038%2FNCPURO1190

7 January 2021

Risk of prostate cancer-specific mortality following biochemical recurrence after radical prostatectomy

1 reference

https://api.crossref.org/works/10.1038%2FNCPURO1190

7 January 2021

Pattern of prostate-specific antigen (PSA) failure dictates the probability of a positive bone scan in patients with an increasing PSA after radical prostatectomy

1 reference

https://api.crossref.org/works/10.1038%2FNCPURO1190

7 January 2021

Bone scan as a stratification variable in advanced prostate cancer

1 reference

https://api.crossref.org/works/10.1038%2FNCPURO1190

7 January 2021

Stratification of patients with metastatic prostate cancer based on extent of disease on initial bone scan

1 reference

https://api.crossref.org/works/10.1038%2FNCPURO1190

7 January 2021

The role of nuclear medicine in monitoring treatment in skeletal malignancy.

1 reference

https://api.crossref.org/works/10.1038%2FNCPURO1190

7 January 2021

Worsening bone scan in the evaluation of antitumor response during hormonal therapy of breast cancer.

1 reference

https://api.crossref.org/works/10.1038%2FNCPURO1190

7 January 2021

Leuprolide therapy for prostate cancer. An association with scintigraphic "flare" on bone scan

1 reference

https://api.crossref.org/works/10.1038%2FNCPURO1190

7 January 2021

Prognostic significance of extent of disease in bone in patients with androgen-independent prostate cancer.

1 reference

https://api.crossref.org/works/10.1038%2FNCPURO1190

7 January 2021

Percentage of the positive area of bone metastasis is an independent predictor of disease death in advanced prostate cancer

1 reference

https://api.crossref.org/works/10.1038%2FNCPURO1190

7 January 2021

Quantitative evaluation of bone metastases in patients with advanced prostate cancer during systemic treatment

1 reference

https://api.crossref.org/works/10.1038%2FNCPURO1190

7 January 2021

Imaging prostate cancer: a multidisciplinary perspective

1 reference

https://api.crossref.org/works/10.1038%2FNCPURO1190

7 January 2021

Computed Tomography — An Increasing Source of Radiation Exposure

1 reference

https://api.crossref.org/works/10.1038%2FNCPURO1190

7 January 2021

Detection of bone marrow involvement in breast cancer with magnetic resonance imaging

1 reference

https://api.crossref.org/works/10.1038%2FNCPURO1190

7 January 2021

Whole-body bone marrow MRI in patients with metastatic disease to the skeletal system

1 reference

https://api.crossref.org/works/10.1038%2FNCPURO1190

7 January 2021

Magnetic resonance imaging versus radionuclide scintigraphy in screening for bone metastases

1 reference

https://api.crossref.org/works/10.1038%2FNCPURO1190

7 January 2021

A prospective study of factors predicting clinically occult spinal cord compression in patients with metastatic prostate carcinoma

1 reference

https://api.crossref.org/works/10.1038%2FNCPURO1190

7 January 2021

Magnetic resonance imaging of the axial skeleton for detecting bone metastases in patients with high-risk prostate cancer: diagnostic and cost-effectiveness and comparison with current detection strategies.

1 reference

https://api.crossref.org/works/10.1038%2FNCPURO1190

7 January 2021

Positron-emission tomography and assessment of cancer therapy

1 reference

https://api.crossref.org/works/10.1038%2FNCPURO1190

7 January 2021

Detection of bone metastases: assessment of integrated FDG PET/CT imaging

1 reference

https://api.crossref.org/works/10.1038%2FNCPURO1190

7 January 2021

2-[18F]fluoro-2-deoxyglucose positron emission tomography for the detection of disease in patients with prostate-specific antigen relapse after radical prostatectomy

1 reference

https://api.crossref.org/works/10.1038%2FNCPURO1190

7 January 2021

Fluorodeoxyglucose positron emission tomography studies in diagnosis and staging of clinically organ-confined prostate cancer

1 reference

https://api.crossref.org/works/10.1038%2FNCPURO1190

7 January 2021

Pilot trial of unlabeled and indium-111-labeled anti-prostate-specific membrane antigen antibody J591 for castrate metastatic prostate cancer.

1 reference

https://api.crossref.org/works/10.1038%2FNCPURO1190

7 January 2021

Advances in positron emission tomography applications for urologic cancers

1 reference

https://api.crossref.org/works/10.1038%2FNCPURO1190

7 January 2021

Evaluation of [11C]-choline positron-emission/computed tomography in patients with increasing prostate-specific antigen levels after primary treatment for prostate cancer

1 reference

https://api.crossref.org/works/10.1038%2FNCPURO1190

7 January 2021

18F-choline PET/CT for initial staging of advanced prostate cancer.

1 reference

https://api.crossref.org/works/10.1038%2FNCPURO1190

7 January 2021

The changing face of prostate cancer

1 reference

https://api.crossref.org/works/10.1038%2FNCPURO1190

7 January 2021

Preoperative nomogram predicting the 10-year probability of prostate cancer recurrence after radical prostatectomy

1 reference

https://api.crossref.org/works/10.1038%2FNCPURO1190

7 January 2021

Baseline staging of newly diagnosed prostate cancer: a summary of the literature

1 reference

https://api.crossref.org/works/10.1038%2FNCPURO1190

7 January 2021

Prostate cancer progression in the presence of undetectable or low serum prostate-specific antigen level

1 reference

https://api.crossref.org/works/10.1038%2FNCPURO1190

7 January 2021

Is prostate-specific antigen a reliable marker of bone metastasis in patients with newly diagnosed cancer of the prostate?

1 reference

https://api.crossref.org/works/10.1038%2FNCPURO1190

7 January 2021

Serum bone alkaline phosphatase levels enhance the clinical utility of prostate specific antigen in the staging of newly diagnosed prostate cancer patients

1 reference

https://api.crossref.org/works/10.1038%2FNCPURO1190

7 January 2021

Metastatic prostate cancer: initial findings of PET with 2-deoxy-2-[F-18]fluoro-D-glucose

1 reference

https://api.crossref.org/works/10.1038%2FNCPURO1190

7 January 2021

Investigations with FDG-PET scanning in prostate cancer show limited value for clinical practice

1 reference

https://api.crossref.org/works/10.1038%2FNCPURO1190

7 January 2021

Value of [11C]choline-positron emission tomography for re-staging prostate cancer: a comparison with [18F]fluorodeoxyglucose-positron emission tomography.

1 reference

https://api.crossref.org/works/10.1038%2FNCPURO1190

7 January 2021

The role of fluorodeoxyglucose, 18F-dihydroxyphenylalanine, 18F-choline, and 18F-fluoride in bone imaging with emphasis on prostate and breast

1 reference

https://api.crossref.org/works/10.1038%2FNCPURO1190

7 January 2021

Radical prostatectomy versus watchful waiting in early prostate cancer

1 reference

https://api.crossref.org/works/10.1038%2FNCPURO1190

7 January 2021

Long-term follow-up of 111In-capromab pendetide (ProstaScint) scan as pretreatment assessment in patients who undergo salvage radiotherapy for rising prostate-specific antigen after radical prostatectomy for prostate cancer

1 reference

https://api.crossref.org/works/10.1038%2FNCPURO1190

7 January 2021

Limited value of bone scintigraphy and computed tomography in assessing biochemical failure after radical prostatectomy

1 reference

https://api.crossref.org/works/10.1038%2FNCPURO1190

7 January 2021

Predicting the outcome of salvage radiation therapy for recurrent prostate cancer after radical prostatectomy

1 reference

https://api.crossref.org/works/10.1038%2FNCPURO1190

7 January 2021

Identifiers

DOI

10.1038/NCPURO1190

1 reference

19 August 2017

1 reference